• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.

作者信息

Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud P A, Mazieres J, Bennouna J

机构信息

Centre Hospitalier Universitaire Nantes, Medical Oncology, Nantes University, 44000, Nantes, France.

Medical Oncology Unit, Clinique Mutualiste de L'Estuaire, Saint-Nazaire, France.

出版信息

Cancer Immunol Immunother. 2023 Jun;72(6):1891-1892. doi: 10.1007/s00262-023-03405-7.

DOI:10.1007/s00262-023-03405-7
PMID:36847863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10198821/
Abstract
摘要

相似文献

1
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.对以下内容的更正：非小细胞肺癌中一线单用帕博利珠单抗或联合铂类化疗的真实世界多中心队列研究，PD-L1≥50
Cancer Immunol Immunother. 2023 Jun;72(6):1891-1892. doi: 10.1007/s00262-023-03405-7.
2
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.在非小细胞肺癌中，一线单用帕博利珠单抗或联合铂类化疗治疗PD-L1≥50的真实世界多中心队列研究。
Cancer Immunol Immunother. 2023 Jun;72(6):1881-1890. doi: 10.1007/s00262-022-03359-2. Epub 2023 Jan 24.
3
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
4
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.在程序性死亡受体配体1（PD-L1）表达≥50%的非小细胞肺癌患者中，一线使用帕博利珠单抗联合或不联合铂类双药化疗。
Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22.
5
Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.信迪利单抗与其他 PD-L1 抑制剂用于非鳞状非小细胞肺癌一线治疗的间接比较。
Future Oncol. 2022 May;18(15):1896-1905. doi: 10.2217/fon-2021-1336. Epub 2022 Mar 21.
6
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.在一项大型多中心真实世界研究中，PD-L1 表达≥50%的 NSCLC 患者接受一线单药 pembrolizumab 治疗后的进展后结局。
Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
7
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.一线免疫治疗进展后，接受挽救性化疗或帕博利珠单抗治疗，联合或不联合局部消融治疗，用于PD-L1≥50%的晚期非小细胞肺癌患者的疗效：来自欧洲队列的真实世界数据
J Thorac Dis. 2019 Dec;11(12):4972-4981. doi: 10.21037/jtd.2019.12.23.
8
Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis.抗 PD-1/PD-L1 联合或不联合化疗作为晚期非小细胞肺癌一线治疗的疗效和安全性：系统评价和网络荟萃分析。
Thorac Cancer. 2022 Feb;13(3):322-337. doi: 10.1111/1759-7714.14244. Epub 2021 Dec 14.
9
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
10
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.免疫检查点抑制剂作为一线治疗方案，单独或联合化疗用于晚期非小细胞肺癌：一项系统评价和网络荟萃分析。
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.

引用本文的文献

1
Outcomes in Patients with Non-Small-Cell Lung Cancer with Brain Metastases: A Real-World Data Study from a Resource-Limited Country.非小细胞肺癌脑转移患者的治疗结果：来自资源有限国家的真实世界数据研究
Cancers (Basel). 2025 May 9;17(10):1603. doi: 10.3390/cancers17101603.